|
Interdepartmental Health Equity Collaborative (formerly FIHET)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIMHD, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINR, ODP
|
Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Interdepartmental Health Equity Collaborative (IHEC). The IHEC was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels.
|
|
Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, SAMHSA
|
NIMH
|
In December 2016, the 21st Century Cures Act was signed into law (Public Law 114-255). Through this Act, the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) was established to address the needs of adults with serious mental illness (SMI) and children and youth with serious emotional disturbance (SED) and their families so that Americans with SMI and SED are able to improve their lives and receive the highest possible standard of care—care that is deeply informed by knowledge of science and medicine. The ISMICC includes representatives from eight federal departments that support programs that address the needs of people with SMI and SED, and is informed and strengthened by the participation of non-federal members, including national experts on health care research, mental health providers, advocates, people with living with mental health conditions, and their families and caregivers. This cross-sector, public-private partnership provides a unique opportunity to share and generate solutions to the problems facing the mental health system. The ISMICC seeks to support a system where individuals with SMI or SED are able to engage effectively with a range of treatment and recovery support services that promote opportunities for people to live well in their communities. A central charge of this committee is to submit two reports to Congress, the first no later than one year after the enactment of the Act, and the second five years following enactment. The ISMICC has five priority areas and corresponding workgroups for these priority areas. Representatives from National Institute of Mental Health sit on each of these workgroups.
|
|
Interdepartmental Substance Use Disorders Coordinating Committee (ISUDCC)
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA
|
NIDA
|
The Secretary of Health and Human Services, in coordination with the Director of the Office of National Drug Control Policy, is required by the SUPPORT for Patients and Communities Act Public Law 115-271 (PDF | 679 KB) to establish an Interdepartmental Substance Use Disorders Coordinating Committee composed of federal and non-federal members to accomplish the following duties: 1. Identify areas for improved coordination of activities, if any, related to substance use disorders, including research, services, supports, and prevention activities across all relevant federal agencies; 2. Identify and provide to the Secretary recommendations for improving federal programs for the prevention and treatment of, and recovery from, substance use disorders, including by expanding access to prevention, treatment, and recovery services; 3. Analyze substance use disorder prevention and treatment strategies in different regions of and populations in the United States and evaluate the extent to which federal substance use disorder prevention and treatment strategies are aligned with State and local substance use disorder prevention and treatment strategies; 4. Make recommendations to the Secretary regarding any appropriate changes with respect to the activities and strategies described in items (1) through (3) above; 5. Make recommendations to the Secretary regarding public participation in decisions relating to substance use disorders and the process by which public feedback can be better integrated into such decisions; and 6. Make recommendations to ensure that substance use disorder research, services, supports, and prevention activities of the Department of Health and Human Services and other federal agencies are not unnecessarily duplicative.
|
|
International Cancer Control Partnership (ICCP)
|
Other
|
CDC
|
NCI
|
The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners assist countries by: (1) Creating and maintaining a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Providing technical assistance to countries working to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Coordinating an online community of practice (through partnership with the University of New Mexico's Project ECHO) for dissemination and utilization of scientific knowledge for National Cancer Control Plan implementation. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets.
|
|
International Cancer Screening Network (ICSN)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI
|
The International Cancer Screening Network (ICSN) is a voluntary consortium of screening practitioners who work in countries that are planning for or implemented population-based cancer screening programs with the mission of reducing the burden of cancer by promoting dialogue and collaborative cancer screening research, evaluation and dialogue regarding the effectiveness of context-specific evidence-based cancer screening programs, including promotion, recruitment and follow-up among other relevant topics. ICSN goals include:
1. To provide global leadership in cancer screening research and evaluation by organizing scientific studies, biennial conferences, consultations, mentorship, training, and by publishing collaborative papers.
2. To create a community of screening practitioners (researchers, evaluators, implementers and screening program staff) to exchange data, evidence, ideas and experiences that advance the field of cancer screening.
3. To assist in the design of studies to evaluate the process and effectiveness of cancer screening programs; to evaluate and promote innovation in cancer screening through new technologies; to enhance the screening process for treatment of screen-detected lesions, among other topics.
4. To be a source of education and dialogue about basic aspects of cancer screening as well as advanced and emerging concepts and technology.
5. To include membership who conducts cancer screening research, develop infrastructure for cancer screening, and establish programs whose goal is to deliver the highest quality health care while producing the maximum benefit to the population and minimizing its harms.
|
|
International Neonatal Consortium
|
Meeting/ Workshop
|
FDA
|
NICHD
|
Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates. “By uniting stakeholders from research institutions, drug developers, regulatory agencies, patient advocacy and other organizations,” said Janet Woodcock, Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (FDA/CDER), “INC can develop practical tools that can be incorporated into clinical trials for neonates, which will then lead to more successful, efficient trials and provide this population with better treatments.”
|
|
International Rare Diseases Research Consortium (IRDiRC) Funders' Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCATS, NCI, NEI, NHGRI, NIAMS, NINDS
|
The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. A number of grand challenges are being addressed through collaborative actions to reach these 2020 goals such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of rare diseases, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures.
|
|
International TB Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
This is a working group of the Federal Tuberculosis (TB) Task Force. The International TB Working Group is chaired and organized by the US Agency for International Development (USAID). It meets monthly to coordinate international TB support.
|
|
Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee
|
Committee, Work group, Advisory group, or Task Force
|
IOS
|
NLM
|
The Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to the Office of the National Coordinator for Health Information Technology (ONC) on standards and implementation specifications to promote interoperability of computer systems and health information.
|
|
Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NIAID, OD/ORS
|
Makes technically-based recommendations to the APHIS/CDC Select Agent and Toxin Program on restricted experiments with Select Agents and Toxins and the exclusion and exemption of attenuated strains. The Committee also conducts a biennial review of the Select Agents and Toxins list for HHS and overlap agents and toxins.
|